BioCentury | Jan 12, 2021
Finance

Jan. 11 Quick Takes: Megarounds for Valo, Visen; plus NuProbe, Sensei

...international family offices, as well as existing investors Cambrian Biopharma, Moore Strategic Ventures, Steve Jurvetson’s Future Ventures...
BioCentury | Oct 9, 2020
Deals

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

...a $28.5 million series AA round co-led by Cambrian Biopharma and H&S Ventures; new investors Future Ventures...
BioCentury | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

...this year, Deep Genomics Inc. raised $40 million in a series B round led by Future Ventures...
BioCentury | Jul 19, 2019
Company News

Management tracks: Iovance, ViiV, Hercules, Pappas and more

Cancer immunotherapy company Iovance Biotherapeutics Inc. (NASDAQ:IOVA) hired Friedrich Graf Finckenstein as CMO. He was global head of oncology translational medicine of the Pharma Research and Early Development (pRED) unit of Roche (SIX:ROG; OTCQX:RHHBY). ViiV...
BioCentury | Oct 4, 2010
Strategy

Times changed

By acquiring ZymoGenetics Inc. for $885 million in cash, Bristol-Myers Squibb Co. will get full ownership of PEG-Interferon lambda in a bet that interferons will remain an essential part of HCV treatment for years to...
BioCentury | May 11, 2009
Strategy

Latent Value Finds a Home

Having refocused its R&D exclusively on immunology as part of a cost-cutting effort, ZymoGenetics Inc. hopes to unlock some downstream value by out-licensing rights to a collection of shelved programs to Seattle Life Sciences Inc....
BioCentury | Mar 8, 2004
Emerging Company Profile

Avera: Neuro NRDO

Although many compounds are shelved for good reasons, Avera Pharmaceuticals Inc. maintains that tapping the cupboard at pharma companies does not mean it will end up with second-rate opportunities. The company expects that the neurological...
Items per page:
1 - 7 of 7
BioCentury | Jan 12, 2021
Finance

Jan. 11 Quick Takes: Megarounds for Valo, Visen; plus NuProbe, Sensei

...international family offices, as well as existing investors Cambrian Biopharma, Moore Strategic Ventures, Steve Jurvetson’s Future Ventures...
BioCentury | Oct 9, 2020
Deals

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

...a $28.5 million series AA round co-led by Cambrian Biopharma and H&S Ventures; new investors Future Ventures...
BioCentury | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

...this year, Deep Genomics Inc. raised $40 million in a series B round led by Future Ventures...
BioCentury | Jul 19, 2019
Company News

Management tracks: Iovance, ViiV, Hercules, Pappas and more

Cancer immunotherapy company Iovance Biotherapeutics Inc. (NASDAQ:IOVA) hired Friedrich Graf Finckenstein as CMO. He was global head of oncology translational medicine of the Pharma Research and Early Development (pRED) unit of Roche (SIX:ROG; OTCQX:RHHBY). ViiV...
BioCentury | Oct 4, 2010
Strategy

Times changed

By acquiring ZymoGenetics Inc. for $885 million in cash, Bristol-Myers Squibb Co. will get full ownership of PEG-Interferon lambda in a bet that interferons will remain an essential part of HCV treatment for years to...
BioCentury | May 11, 2009
Strategy

Latent Value Finds a Home

Having refocused its R&D exclusively on immunology as part of a cost-cutting effort, ZymoGenetics Inc. hopes to unlock some downstream value by out-licensing rights to a collection of shelved programs to Seattle Life Sciences Inc....
BioCentury | Mar 8, 2004
Emerging Company Profile

Avera: Neuro NRDO

Although many compounds are shelved for good reasons, Avera Pharmaceuticals Inc. maintains that tapping the cupboard at pharma companies does not mean it will end up with second-rate opportunities. The company expects that the neurological...
Items per page:
1 - 7 of 7